Loading
Governments and philanthropies would pay a company a one-off lump sum, set by auction to reflect the drug's social value, for the patent on a cancer drug with a large benefit in a common cancer, then let generic makers supply it worldwide at competitive prices. A pilot fund would buy out one or two oncology patents.
Patent buyouts (proposed by Kremer and others) replace monopoly pricing with a lump sum reflecting the drug's social value, after which the drug enters generic competition. Cancer drugs with large survival benefits in common cancers (for example adjuvant immunotherapy or a highly effective targeted agent) are candidates where the deadweight loss of high prices is largest. The proposal is a pilot fund, capitalised by a coalition of governments and philanthropies, that runs an auction-based valuation and buys out one or two oncology patents for global generic supply, with a prize element for the developer.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value, Most of the world has almost no cancer care.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value, Most of the world has almost no cancer care.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value, Most of the world has almost no cancer care.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value, Most of the world has almost no cancer care.
Shares The high price of anticancer drugs: origins, implications, barriers, solutions, Prices and value.